Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis

Tom Decroo; Kya Jai Maug Aung; Mohamed Anwar Hossain; Mourad Gumusboga; Nimer Ortuno-Gutierrez; Bouke Catherine De Jong; Armand Van Deun

doi:10.1183/13993003.02124-2021

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis

Eur Respir J. 2022 Mar 24;59(3):2102124. doi: 10.1183/13993003.02124-2021. Print 2022 Mar.

Authors

Tom Decroo¹, Kya Jai Maug Aung², Mohamed Anwar Hossain², Mourad Gumusboga³, Nimer Ortuno-Gutierrez⁴, Bouke Catherine De Jong³, Armand Van Deun⁵

Affiliations

¹ Institute of Tropical Medicine, Unit of HIV and TB, Dept of Clinical Sciences, Antwerp, Belgium tdecroo@itg.be.
² Damien Foundation Bangladesh, Dhaka, Bangladesh.
³ Institute of Tropical Medicine, Unit of Mycobacteriology, Dept of Biomedical Sciences, Antwerp, Belgium.
⁴ Damien Foundation, Brussels, Belgium.
⁵ Independent Consultant, Leuven, Belgium.

Abstract

In the original short treatment regimen for rifampicin-resistant tuberculosis, bedaquiline proved an adequate core drug for fluoroquinolone resistance, ensuring early conversion and relapse-free cure. Use of linezolid did not have the same early effect. https://bit.ly/3gWuf9z

Publication types

Letter

MeSH terms

Antitubercular Agents / therapeutic use
Diarylquinolines / therapeutic use
Fluoroquinolones / therapeutic use
Humans
Rifampin* / therapeutic use
Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

Antitubercular Agents
Diarylquinolines
Fluoroquinolones
bedaquiline
Rifampin